Remove 2019 Remove Chemotherapy Remove Immunization
article thumbnail

Intratumoural viral delivery improves glioblastoma survival

European Pharmaceutical Review

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

article thumbnail

AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic

European Pharmaceutical Review

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis extends Kaiku digital patient monitoring partnership

pharmaphorum

Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

“If we work closely with government stakeholders and possibly collaborate on developing innovative access schemes for rare diseases, cancers, immune and inflammatory disorders, we can encourage greater participation by established biopharmas and stimulate the growth of entrepreneurial local companies in the region.”. million in 2030.

article thumbnail

Roche hit by failure of TIGIT drug tiragolumab in lung cancer

pharmaphorum

The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

article thumbnail

Sobi gets EU nod for Doptelet in rare blood disorder ITP

pharmaphorum

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug. Sobi acquired Doptelet via its $915 million takeover of Dova Pharmaceuticals in 2019, adding to its haematology and rare disease franchise.